Evidence map›Paper›PMID 40434532›Full record

ArticleOphthalmology and therapy2025

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study.

Masayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, Kazuaki Kadonosono, Hitoshi Ohno, Ryusaburo Mori, Hidetaka Matsumoto, Ippei Nagamori, Yuki Murata, Tina Maio-Twofoot and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06699914 (A Retrospective, 12-month, Multicenter Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06699914 completednot on this map

A Retrospective, 12-month, Multicenter Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD) - the PHEASANT Study - a Study Following the Master Protocol

TypeobservationalSponsorNovartis PharmaceuticalsRan2022 to 2023Enrolled438ConditionsNeovascular Age-Related Macular Degeneration
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masayuki OhnakaDepartment of Ophthalmology, Kansai Medical University, Osaka, Japan. ohnakam@hirakata.kmu.ac.jp.
Yoichi SakuradaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Kofu, Yamanashi, Japan.
Atsushi HayashiDepartment of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Kazuaki KadonosonoDepartment of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Kanagawa, Japan.
Hitoshi OhnoChofu Eye Clinic, Tokyo, Japan.
Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Hidetaka MatsumotoDepartment of Ophthalmology, Gunma University Graduate School of Medicine, Gunma, Japan.
Ippei NagamoriNovartis Pharma K.K., Tokyo, Japan.
Yuki MurataNovartis Pharma K.K., Tokyo, Japan.
Tina Maio-TwofootNovartis AG, Basel, Switzerland.
Helene KarcherNovartis AG, Basel, Switzerland.
Hidenori TakahashiDepartment of Ophthalmology, Jichi Medical University, Tochigi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to evaluate the real-world outcomes of brolucizumab use in Japanese patients with neovascular age-related macular degeneration (nAMD).

methodsPHEASANT was a retrospective, multicenter, single-arm cohort study. The study included 438 patients, of whom 123 were treatment-naïve and 315 were pre-treated. The primary outcome was retinal fluid (subretinal fluid [SRF] and intraretinal fluid [IRF]) resolution at month 12, with change in visual and retinal anatomy parameters and safety assessed as key secondary outcomes.

resultsAt baseline in the treatment-naïve cohort, 10.1% (n = 7/69) of patients were free of retinal fluid, increasing to 62.3% (n = 43/69) at month 12. In the pre-treated cohort, 14.9% (n = 30/201) of patients were free of retinal fluid at baseline, increasing to 43.8% (n = 88/201) at month 12. The median (interquartile range [IQR]) injection interval for pre-treated patients at month 12 was extended by 21 (7.0-35.0) days. The overall intraocular inflammation rate (including the rate of retinal vasculitis/retinal occlusive vasculitis of 0.46% [2/438]) was 8.4% (n = 37/438).

conclusionIn a real-world clinical setting, brolucizumab was effective at drying the retina in treatment-naïve and pre-treated Japanese nAMD patients and therefore has the potential to reduce the treatment burden by prolonging injection intervals. Safety outcomes support the overall favorable benefit/risk profile of brolucizumab. CLINICALTRIALS: GOV IDENTIFIER: NCT06699914.

Indexed as

Anti-VEGFBrolucizumabNeovascular age-related macular degenerationReal-worldRetinal fluid

Identifiers

PMID40434532
PMCPMC12167219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.